Literature DB >> 27648129

PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.

Wei-Wei Deng1, Lei Wu1, Lin-Lin Bu1, Jian-Feng Liu1, Yi-Cun Li1, Si-Rui Ma1, Guang-Tao Yu1, Liang Mao1, Wen-Feng Zhang2, Zhi-Jun Sun3.   

Abstract

P21 activated kinase 2 (PAK2) is a member of Group I PAKs family and highly expressed in various cancers. Current studies have demonstrated that PAK2 played a pivotal role in tumor progression. However, the role of PAK2 in salivary adenoid cystic carcinoma is still unclear. This study aims to explore the expression and the function of PAK2 in AdCC. Human salivary gland tissue microarray, including 18 normal salivary glands (NSG), 12 pleomorphic adenoma (PMA) and 72 AdCC, and immunohistochemistry were used to evaluate the expression of PAK2. The result showed that PAK2 was significantly increased in AdCC compared with NSG and PMA. Then the Pearson correlation analysis using serial tissue sections showed a close correlation of PAK2 with Cyclin D1, Phospho-STAT3 at Tyrosine 705 (p-STAT3) and Ki-67. Further in vitro study utilizing PAK2 knockdown via siRNA transfection revealed significantly reduced migration and proliferation of AdCC cell lines compared with control group. Knockdown of PAK2 decreased the expression of Cyclin D1 in AdCC cell lines. In addition, the inhibition of STAT3 reduced the expression of PAK2 in AdCC cell lines. These findings suggested that PAK2 promotes AdCC cell migration and proliferation and may be a potential therapeutic target.

Entities:  

Keywords:  P21 activated kinase 2; adenoid cystic carcinoma; migration; proliferation

Year:  2016        PMID: 27648129      PMCID: PMC5009391     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  35 in total

Review 1.  A tale of two Paks.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Biol Cell       Date:  2008-02       Impact factor: 4.458

2.  Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2.

Authors:  T Rudel; G M Bokoch
Journal:  Science       Date:  1997-06-06       Impact factor: 47.728

3.  Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma.

Authors:  Yizhou Zhang; Shoichi Takahashi; Akiko Tasaka; Tadahiko Yoshima; Hidenori Ochi; Kazuaki Chayama
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

4.  Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms.

Authors:  Salvatore J Coniglio; Salvatore Zavarella; Marc H Symons
Journal:  Mol Cell Biol       Date:  2008-04-14       Impact factor: 4.272

5.  Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.

Authors:  Shuaili Chen; Theresa Auletta; Ostap Dovirak; Christina Hutter; Karen Kuntz; Samira El-ftesi; Jude Kendall; Haiyong Han; Daniel D Von Hoff; Raheela Ashfaq; Anirban Maitra; Christine A Iacobuzio-Donahue; Ralph H Hruban; Robert Lucito
Journal:  Cancer Biol Ther       Date:  2008-11-21       Impact factor: 4.742

6.  Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck.

Authors:  Myung-Whun Sung; Kwang Hyun Kim; Jeong-Whun Kim; Yang-Gi Min; Weon-Jin Seong; Jong-Lyel Roh; Sang Joon Lee; Tack-Kyun Kwon; Seok Woo Park
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-11

7.  Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.

Authors:  Craig W Menges; Eleonora Sementino; Jacqueline Talarchek; Jinfei Xu; Jonathan Chernoff; Jeffrey R Peterson; Joseph R Testa
Journal:  Mol Cancer Res       Date:  2012-07-12       Impact factor: 5.852

8.  PAK signaling in cancer.

Authors:  Diana Zi Ye; Jeffrey Field
Journal:  Cell Logist       Date:  2012-04-01

9.  Group I Paks as therapeutic targets in NF2-deficient meningioma.

Authors:  Hoi-Yee Chow; Biao Dong; Sergio G Duron; David A Campbell; Christy C Ong; Klaus P Hoeflich; Long-Sheng Chang; D Bradley Welling; Zeng-Jie Yang; Jonathan Chernoff
Journal:  Oncotarget       Date:  2015-02-10

Review 10.  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.

Authors:  Young Kwang Chae; Su Yun Chung; Andrew A Davis; Benedito A Carneiro; Sunandana Chandra; Jason Kaplan; Aparna Kalyan; Francis J Giles
Journal:  Oncotarget       Date:  2015-11-10
View more
  6 in total

1.  MicroRNA miR-4779 suppresses tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3.

Authors:  Kyung Hee Koo; Heechung Kwon
Journal:  Cell Death Dis       Date:  2018-01-23       Impact factor: 8.469

Review 2.  Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.

Authors:  Xing-Hua Xiao; Lin-Chen Lv; Jing Duan; Ye-Meng Wu; Shu-Jin He; Zhen-Zhen Hu; Li-Xia Xiong
Journal:  Molecules       Date:  2018-03-29       Impact factor: 4.411

3.  PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect.

Authors:  Amit Gupta; Athira Ajith; Smriti Singh; Rajendra Kumar Panday; Atul Samaiya; Sanjeev Shukla
Journal:  Cell Death Dis       Date:  2018-08-01       Impact factor: 8.469

4.  hsa_circ_0013401 Accelerates the Growth and Metastasis and Prevents Apoptosis and Autophagy of Neuroblastoma Cells by Sponging miR-195 to Release PAK2.

Authors:  Shibo Zhu; Xiangliang Tang; Xiaofeng Gao; Jingqi Zhang; Yanhong Cui; Dian Li; Wei Jia
Journal:  Oxid Med Cell Longev       Date:  2021-11-22       Impact factor: 6.543

5.  Transcriptome analyses identify hub genes and potential mechanisms in adenoid cystic carcinoma.

Authors:  Hong-Bing Liu; Guan-Jiang Huang; Meng-Si Luo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

6.  Long non-coding RNA ZEB1-AS1 promotes colon adenocarcinoma malignant progression via miR-455-3p/PAK2 axis.

Authors:  Xin Ni; Yuting Ding; Haitao Yuan; Jinmin Shao; Yan Yan; Rouyu Guo; Wenkang Luan; Min Xu
Journal:  Cell Prolif       Date:  2019-12-12       Impact factor: 6.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.